Corona Remedies Profile
Key Indicators
- Authorised Capital ₹ 61.17 Cr
- Paid Up Capital ₹ 61.16 Cr
- Company Age 20 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 250.00 Cr
- Satisfied Charges ₹ 112.58 Cr
- Revenue Growth 7.37%
- Profit Growth -100.57%
- Ebitda -83.09%
- Net Worth -5.01%
- Total Assets -3.81%
About Corona Remedies
Corona Remedies Limited (CRL) is a leading Public Limited Indian Non-Government Company incorporated in India on 27 August 2004 and has a history of 20 years and five months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 61.17 Cr and a paid-up capital of Rs 61.16 Cr.
The company currently has active open charges totaling ₹250.00 Cr. The company has closed loans amounting to ₹112.58 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Corona Remedies Limited India are Bhagya Dave as Company Secretary, Bhavin Bhagat as Cfo, and Niravkumar Mehta as Ceo. Ameetkumar Desai, Kshitij Sheth, Ankur Mehta, and Four other members serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24231GJ2004PLC044656
- Company No.
044656
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
27 Aug 2004
- Date of AGM
19 Jun 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Corona Remedies Limited offer?
Corona Remedies Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Antidiabetic Medicine, TB, Tumor & Cancer Drugs, Anti Cancer Injection, Anti Cancer Medicines, Diabetes Medicine, Common Disease Medicines, Pharmaceutical Tablets, Brain & Nervous System Drugs, Antiepileptic Drugs.
Who are the key members and board of directors at Corona Remedies?
Executive Team (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankur Mehta  | Managing Director | 27-Aug-2004 | Current |
| Nirav Mehta | Managing Director | 30-May-2007 | Current |
| Bhagya Dave | Company Secretary | 11-Nov-2023 | Current |
| Bhavin Bhagat | CFO | 29-Oct-2024 | Current |
| Niravkumar Mehta | CEO | 04-Sep-2024 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kshitij Sheth | Nominee Director | 30-Mar-2021 | Current |
| Ameetkumar Desai | Director | 22-Nov-2022 | Current |
| Kirtikumar Mehta | Director | 27-Aug-2004 | Current |
| Viral Sitwala | Whole-Time Director | 01-Jan-2010 | Current |
| Monica Kanuga | Director | 24-Oct-2024 | Current |
Financial Performance of Corona Remedies.
Corona Remedies Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.37% increase. The company also saw a substantial fall in profitability, with a 100.57% decrease in profit. The company's net worth dipped by a decrease of 5.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Corona Remedies?
In 2024, Corona Remedies had a promoter holding of 72.50% and a public holding of 27.50%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ambuja Cements LimitedAmeetkumar Desai is a mutual person
Jm Financial Asset Reconstruction Company LimitedAmeetkumar Desai is a mutual person
La Renon Healthcare Private LimitedKshitij Sheth is a mutual person
Shilp Gravures LimitedMonica Kanuga is a mutual person
Globalbees Brands Private LimitedKshitij Sheth is a mutual person
Hester Biosciences LimitedAmeetkumar Desai is a mutual person
Charges (Loans)
₹250.00 Cr
₹112.58 Cr
Charges Breakdown by Lending Institutions
- Citi Bank N.A. : 200.00 Cr
- Others : 50.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Dec 2023 | Others | ₹50.00 Cr | Open |
| 07 Jul 2023 | Citi Bank N.A. | ₹200.00 Cr | Open |
| 28 Aug 2019 | Others | ₹3.28 M | Satisfied |
| 22 Aug 2019 | Others | ₹6.06 M | Satisfied |
| 02 Feb 2019 | Hdfc Bank Limited | ₹50.00 Cr | Satisfied |
How Many Employees Work at Corona Remedies?
Corona Remedies has a workforce of 4223 employees as of Nov 19, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Corona Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Corona Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
